A-V Fistula Needle
Bd Becton Dickinson Vacutainer Systems Preanalytic
FDA Clearance Information
The a-v fistula needle by Bd Becton Dickinson Vacutainer Systems Preanalytic was cleared via the FDA 510k pathway on August 17, 1978. It is classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Accessing an established arteriovenous fistula for hemodialysis.
- Providing vascular access for blood withdrawal and return during dialysis treatment.
Clinical Applications
- Cannulation of an AV fistula before hemodialysis.
- Withdrawal of blood from the fistula for extracorporeal dialysis.
- Return of dialyzed blood to the patient through the fistula.
- Repeated vascular access during scheduled hemodialysis treatments.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- Needle gauge, length, and configuration should be selected by trained dialysis staff based on the fistula, prescribed blood-flow rate, and patient anatomy.
- The needle must be handled using sterile technique and secured to reduce the risk of dislodgement, bleeding, infiltration, or loss of access.
- The needle is intended for vascular access through an AV fistula and should not be assumed to be appropriate for central venous, arterial, or graft access unless the labeling specifically permits it.
- This is a needle rather than an implanted device; MRI concerns generally relate to the needle's material and whether it remains in place. Follow the manufacturer's MRI labeling and institutional policy.
- Do not use through an infected, thrombosed, severely stenotic, or otherwise unsuitable fistula. Assessment by qualified dialysis clinicians is required before cannulation.
Frequently Asked Questions
What are the clinical indications for a-v fistula needle?
The a-v fistula needle is indicated for vascular access in patients undergoing hemodialysis, specifically for cannulating arteriovenous fistulas.
What outcomes have been reported in clinical studies?
Studies report outcomes related to hemodialysis adequacy, such as KT/V and access recirculation, as well as pain management during cannulation.
What complications have been reported?
Safety data indicate complications such as potential damage to the arteriovenous fistula, which can lead to access failure.